Interactive Medica, the leading Pharma SaaS provider, today launches IM Strategic Selling, a new Software as a Service (SaaS) solution that enables promotional teams, managers and executives to identify, collaborate, plan and manage goals, strategies and activities for current and potential Key Accounts. biotechnology fund
PAREXEL International Corporation (Nasdaq: PRXL), a leading global biopharmaceutical services provider, announced it has reached a milestone in managing oncology-based clinical trials over the last five years, which have involved over 175,000 patients in hundreds of programs across 80 countries. PAREXEL will be marking this milestone during the American Society of Clinical Oncology (ASCO) Annual Meeting, to be held May 29 – June 2, 2009 in Orlando, Florida. biotechnology fund
Sanofi Pasteur, the vaccines division of the sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), announced today it has received the new influenza A(H1N1) seed virus, enabling the world’s leading manufacturer of influenza vaccines to begin the production process for an A(H1N1) vaccine. biotechnology fund
Bioasia S Biotechnology Development FundVivo Ventures is a life-sciences focused venture capital firm formed in 1996 with over $650M under management. Vivo Ventures is currently making investments from its $275M sixth .
Bioasia S Biotechnology Development FundVivo Ventures is a life-sciences focused venture capital firm formed in 1996 with over $650M under management. Vivo Ventures is currently making investments from its $275M sixth .
Does biotech win if VCs get a better chance at SBIR? : MedCity NewsLisa Kurek, managing partner of Biotechnology Business Consultants in Michigan, thinks any change should include a re-definition of venture capital firms. “There’s a difference between large venture funds or the institutional investors .
